Key facts
- Ostial’s last known valuation is $18.4M (Sep 2022).
- It has raised $15.4M across 2 recorded rounds; the latest was Early Stage VC ($7.7M) in Sep 2022.
- Notable investors include AMED Ventures, Delos Capital Partners, Incept, Techlink Ventures.
- Ostial has filed 2 Form Ds with the SEC since 2019, most recently Sep 2022 ($7.7M sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Ostial
Funding rounds
2 roundsAbout Ostial
Operator of a medical technology company intended to address the clinical challenges of aorto-ostial interventions. The company aims to arm physicians with advanced innovation that addresses the treatment of high-risk areas in coronary and peripheral cases, and its dual-balloon angioplasty catheter is designed to overcome challenges of aorto-ostial stenting by delivering complete stent apposition at the ostium, enabling healthcare providers to achieve maximal stent wall apposition after post-dilation.
- Sector
- Healthcare
- HQ
- Campbell, CA, United States
- Founded
- 2010
- Employees
- 18
- Website
- vergemedical.com/
- Ownership
- Privately Held (backing)
Ostial doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ostial shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ostial in its N-PORT filings yet. We sweep new filings monthly.